麻豆传媒

An American Cancer Society feature focuses on the challenges of a cancer survivor now because of the COVID-19 pandemic.

During the COVID-19 pandemic, patients with should have an abbreviated course of high-intensity radiation therapy and should delay surgery, an international panel of experts recommended. (University of Leeds, Radiotherapy & Oncology)

An oncologist summarizes an "excellent article" about a common to both COVID-19 and prostate cancer. (ASCO Connection)

A leading breast cancer specialist reflects on toward improving outcomes and curing the disease. (Journal of Clinical Oncology)

Exposure to even low-level air pollution may in ways that predispose people to cancer and other diseases. (Monash University, Environmental International)

An oral drug performed as well as an injectable one for preventing . (American College of Cardiology)

A severely ill patient with multiple myeloma and COVID-19 infection with tocilizumab (Actemra), a drug used for treatment-induced inflammation, and also suggested that COVID-19 symptoms might differ in patients with hematologic malignancies. (Blood Advances)

Pfizer and Eli Lilly prevailed against a alleging the erectile dysfunction drugs sildenafil (Viagra) and tadalafil (Cialis) cause cancer. (Pharmafile)

Good news-bad news for women about radiation therapy: than in men but causes more severe toxicity. (University of South Australia)

Knowing about a may help patients live longer. (Psycho-Oncology)

A phase III clinical trial of the antibody-drug conjugate sacituzumab govitecan in triple-negative breast cancer because of "compelling efficacy across multiple study endpoints," Immunomedics announced.

Cancer Research UK, which funds about half of all cancer research in England, announced a £44 million ($54 million) as a result of fundraising shortfalls.

A review of 20 published studies showed a between increased consumption of dietary fiber and decreased risk of breast cancer. (Cancer)

Regular exercise was associated with . (Roswell Park Comprehensive Cancer Center)

The FDA approved encorafenib (Braftovi) in combination with cetuximab (Erbitux) for that progressed on prior therapy, according to a statement from Pfizer.

Comment